India allows Serum Institute to enrol 7-11 year olds in COVID-19 vaccine trial

It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.

  • Updated On Sep 28, 2021 at 02:57 PM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
BENGALURU -India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its COVID-19 vaccine trial as the country prepares to protect children from the coronavirus.

It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.

"After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol," a subject expert panel of the Central Drugs Standard Control Organization said.

Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of U.S. drugmaker Novavax's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.

Advt
So far, only drugmaker Zydus Cadila's DNA COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.

  • Published On Sep 28, 2021 at 02:53 PM IST
Be the first one to comment.
Comment Now

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App